Achieving tissue-level perfusion in the setting of acute myocardial infarction.

Abstract

Treatment for ST-elevation myocardial infarction (MI) has advanced rapidly in the last few years with improvements in early fibrinolytic therapy, primary percutaneous revascularization, and use of potent platelet glycoprotein IIb/IIIa inhibitors. It is now obvious that establishing epicardial patency after myocardial infarction is not synonymous with tissue-level perfusion. Techniques and therapies are now available that measure true tissue-level perfusion and that may improve tissue-level perfusion after myocardial infarction.

• Authors: D Mukherjee, D J Moliterno
• Journal: The American journal of cardiology (Am J Cardiol) Vol. 85 Issue 8A Pg. 39C-46C (Apr 27 2000) ISSN: 0002-9149 [Print] United States
• PMID: 10793179 (Publication Type: Journal Article, Review)

Chemical References

• Antibodies, Monoclonal
• Immunoglobulin Fab Fragments
• Platelet Aggregation Inhibitors
• Platelet Glycoprotein GPIIb-IIIa Complex
• Abciximab

Topics

• Abciximab
• Animals
• Antibodies, Monoclonal (therapeutic use)
• Coronary Thrombosis (physiopathology)
• Heart (physiopathology)
• Humans
• Immunoglobulin Fab Fragments (therapeutic use)
• Myocardial Infarction (drug therapy, physiopathology)
• Myocardial Reperfusion
• Myocardial Reperfusion Injury (physiopathology)
• Platelet Aggregation (physiology)
• Platelet Aggregation Inhibitors (therapeutic use)
• Platelet Glycoprotein GPIIb-IIIa Complex (therapeutic use)
• Regional Blood Flow